Johnny Mahlangu to Antibodies, Bispecific
This is a "connection" page, showing publications Johnny Mahlangu has written about Antibodies, Bispecific.
Connection Strength
6,030
-
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies. Expert Rev Hematol. 2024 Oct; 17(10):741-748.
Score: 0,915
-
Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
Score: 0,777
-
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar; 27(2):221-228.
Score: 0,712
-
Emicizumab for the prevention of bleeds in hemophilia A. Expert Opin Biol Ther. 2019 08; 19(8):753-761.
Score: 0,636
-
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
Score: 0,613
-
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
Score: 0,602
-
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
Score: 0,204
-
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775.
Score: 0,187
-
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
Score: 0,181
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
Score: 0,178
-
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41.
Score: 0,177
-
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
Score: 0,175
-
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
Score: 0,172
-
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
Score: 0,165
-
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
Score: 0,153
-
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
Score: 0,139
-
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
Score: 0,046